The spin-off RetinaReadRisk has been created for marketing software and a mobile system based on artificial intelligence to detect diabetic retinopathy in the early stages

by GENESIS Biomed

3 years ago
RetinaReadRisk, diabetic retinopathy

The test to detect diabetic retinopathy is an examination of the fundus of the eye. In Catalonia it is carried out in certain primary care centers (CAP), mostly located in cities. In the future, the a...

What is meant by Off-label

by GENESIS Biomed

3 years ago
on-label, Off-label

Off-label medicines, which are those prescribed under conditions other than those authorized in their SmPC, and therefore not covered by the regulatory agency for commercialization for that purpose, b...

Negotiating a Round in the health sector (Part 2) The roadshow and the negotiation of the deal

by GENESIS Biomed

3 years ago
pre-money valuation, equity, roadshow

This article with the most representative slides to start the roadshow, will allow us to face with guarantees the success of the journey we will undertake in the negotiation of our investment round wi...

DIGI-HEART: The digital cardiac mapping tool based on Digital Twins

by GENESIS Biomed

3 years ago
DIGI-HEART

DIGI-Heart project is developing a software to digitally simulate the real cardiac environment of any patient (digital twins) thanks to the close collaboration between Corify Care, GENESIS Biomed and ...

GENESIS Biomed continues growing and adding value in biomedical sector

by GENESIS Biomed

4 years ago
GENESIS Biomed, GENESIS Tech Transfer Boost

GENESIS Biomed, a consultancy firm that specialises in early-stage R&D projects in the biomedical sector, expects to close out 2022 with record turnover of €1.6 million, up 28% from the previous yea...

The Investor Deck, the startup’s business card

by GENESIS Biomed

4 years ago
Investor Deck

The Investor Deck can be described as the business card of a entrepreneurship project where through an executive presentation, thus summarized, of between 10-15 slides the investor can obtain the esse...

Value-based medicine and Risk Sharing Agreement

by GENESIS Biomed

4 years ago
“Patient Value”, Risk sharement agreement

The development of more sophisticated and high-cost treatments with a high preponderance of advanced therapies suggests that this business model is expected to be imposed in more and more cases, imply...

Diabetic patients in rural areas will be able to be diagnosed with diabetic retinopathy in the early stages of the disease thanks to a mobile system

by GENESIS Biomed

4 years ago
diabetic retinopathy

It has been developed a software and a system based on artificial intelligence to diagnose the diabetic retinopathy, a common eye disorder in patients with type 2 diabetes, which is the leading cause ...

Law of Science, the missed opportunity for spin-off creation

by GENESIS Biomed

4 years ago
Law on Science, Technology and Innovation (Law 17/2022)

The new Law on Science, Technology and Innovation (Law 17/2022) does not remove the obligation for public institutions to participate in a spin-off if they want to lift the incompatibilities of resear...

10 projects from the Xartec Salut network are advised by GENESIS Biomed within the framework of the Venture Builder programme

by GENESIS Biomed

4 years ago
Venture Builder Programme, Xartec Salut

Within the framework of the Venture Builder Programme, a mechanism promoted by Xartec Salut to accelerate the creation of spin-off companies, GENESIS Biomed has collaborated during the years 2021 and ...

FiSPlat, a primary care tool for liver fibrosis screening

by GENESIS Biomed

4 years ago
FiSPlat, fibrosis hepática, cirrosis hepática, EIT Health

ASPY Prevención has started a collaboration with Hospital Clínic de Barcelona within the framework of the European project FiSPlat, financed by EIT Health. Within the project, ASPY Prevención will ...

Negotiating a Round in the health sector

by GENESIS Biomed

4 years ago
Venture Capital

Dialogue with investors is no easy task for entrepreneurs in the healthcare sector. We will focus more on how to negotiate a round in the health Venture Capital investor sector in this article,